EGFR and head and neck squamous cell carcinoma: With VEGF-TKIs exhibiting modest benefit in SCCHN to date, either as monotherapy or in combination with chemotherapy or EGFR inhibitors, a more enticing area of interest is their use in combination with immunotherapy.